Biotech Stocks Are Getting Smashed

BiotechBloomberg.comiShares Biotechnology Index

The stock market is selling off today, and once again it’s being led down by the momentum stocks.

One red-hot industry that continues to get smoked is biotechnology.

The iShares Biotechnology Index (IBB) is down a whopping 6.1%.

Among the big losers are Alexion Pharmaceuticals (-7.4%), Gilead Sciences (-6.8%), and Vertex Pharmaceuticals (-6.1%).

“I frankly just don’t know why biotech is off so much today,” said Mark Schoenebaum, a biotech and pharmaceuticals analyst for ISI Group.

The IBB index is now down 19% from its February high.

The industry has seen huge numbers of IPOs in the last year, which has some folks wondering if this is just the bursting of a bubble.

Meanwhile, the industry analysts have generally remained bullish on the industry based on the long-term profit potential of drugs in the developmental and regulatory pipeline.

“Large cap biotech is now trading at a 2015 and 2016 PE discount to the S&P500!” exclaimed Credit Suisse’s Ravi Mehrotra and Koon Ching in a recent note to clients.

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.